{"id":"W1938050263","doi":"10.1200/jco.2014.32.4_suppl.lba1","title":"Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre","funders":"","keywords":"Enzalutamide; Medicine; Interim analysis; Placebo; Clinical endpoint; Hazard ratio; Internal medicine; Prostate cancer; Population; Docetaxel; Asymptomatic; Oncology; Cancer; Randomized controlled trial; Gastroenterology; Urology; Confidence interval; Androgen receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00199371,0.001008174,0.00173219,0.0002699328,0.0002941671,0.00076777,0.0005680302,0.0008826123,0.002175126],"category_scores_gemma":[0.0007168832,0.0004600225,0.001338998,0.000299302,0.000495961,0.0004314771,0.000271435,0.001438279,0.0005544569],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005705291,"about_ca_system_score_gemma":0.001257403,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002094815,"about_ca_topic_score_gemma":0.008144726,"domain_scores_codex":[0.9996033,0.0002234462,0.0000182528,0.00005085811,0.00004991002,0.00005423135],"domain_scores_gemma":[0.9994899,0.00009301682,0.0001298985,0.00003432281,0.00004756316,0.0002052876],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8166297,0.02974772,0.02113824,0.001198778,0.004347636,0.0002204673,0.0002181062,0.00146404,0.02047224,0.0002159467,0.005375301,0.09897181],"study_design_scores_gemma":[0.7506678,0.1764501,0.06138533,0.0000900437,0.003111706,0.000261323,0.00007307206,0.0007384692,0.002203924,0.0002120175,0.004762346,0.00004374766],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9820393,0.009164893,0.0005746055,0.0007899734,0.0001279155,0.001971105,0.002985853,0.0001142431,0.002232064],"genre_scores_gemma":[0.9806882,0.005350669,0.001904831,0.001679644,0.0002427853,0.001492118,0.005569584,0.00004246268,0.003029642],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002175126,"threshold_uncertainty_score":0.01054388,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1163475950626397,"score_gpt":0.5176789045011821,"score_spread":0.4013313094385424,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}